Pertuzumab targets the extracellular domain II of HER2, can inhibit the heterodimerization of HER2 with HER-1, -3, and -4, block downstream signaling pathways, and regulate the proliferation and apoptosis of tumor cells (Fig. 1) [13, 14]. The gene discussed is ERBB2; the disease is neoplasm.